The Hemodynamic Effects of CGRP After Glibenclamide Administration in Healthy Volunteers
NCT ID: NCT04231617
Last Updated: 2020-09-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2020-01-20
2020-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Sumatriptan and Placebo on CGRP Induced Headache
NCT03542357
Investigation of Vasodilation and Intensity of Headache Triggered by Glucagon Like Peptide-1 in Humans
NCT04232605
Glyceryl-Trinitrate-Induced Headache in Patients With Familial Hemiplegic Migraine
NCT00541736
PGI2 Induced Headache and Cerebral Haemodynamics in Healthy Volunteers
NCT00291395
The Hemodynamic Effects of PACAP38 After Glibenclamide Administration in Healthy Volunteers
NCT04960657
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The aim of the study is to investigate the vascular effect of CGRP after glibenclamide administration.
Repeated measurements covering the arteria radialis (RA), superficiel temporal artery (STA) and middle cerebral artery (MCA) before and after glibenclamide/placebo administration and CGRP infusion.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CGRP and glibenclamide
Participants will recieve CGRP infusion after glibenclamide/placebo administration
glibenclamide
Oral administration of glibenclamide or placebo. To investigate the role of CGRP on cranial arteries in healthy volunteers after glibenclamide/placebo administration .
CGRP infusion
CGRP infusion
CGRP and placebo
Participants will recieve CGRP infusion after glibenclamide/placebo administration
CGRP infusion
CGRP infusion
Placebo
placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
glibenclamide
Oral administration of glibenclamide or placebo. To investigate the role of CGRP on cranial arteries in healthy volunteers after glibenclamide/placebo administration .
CGRP infusion
CGRP infusion
Placebo
placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18-60 years.
* 50-100 kg.
* Women of childbearing potential must use adequate contraception
Exclusion Criteria
* Migraine or any other type of headache (except episodic tension-type headache less than once a month)
* Daily intake of any medication except contraceptives
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Danish Headache Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohammad Al-Mahdi Al-Karagholi
MD, PhD student, Principal investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Danish headache center
Glostrup Municipality, Copenhagen, Denmark
Mohammad Al-Mahdi Al-Karagholi
København S, Danmark, Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-19065735
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.